

Status: Currently Official on 17-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-37D06194-CD47-41B2-806F-04B676123CC0_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M33210_02_01
 DOI Ref: 2yql7

© 2025 USPC
 Do not distribute

Floxuridine for Injection

DEFINITION

Floxuridine for Injection is lyophilized Floxuridine suitable for intra-arterial infusion. It contains NLT 90.0% and NMT 110.0% of the labeled amount of floxuridine ($C_9H_{11}FN_2O_5$).

IDENTIFICATION

Change to read:

- **A.** [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Ultraviolet-Visible Spectroscopy: 197U](#) ▲ (CN 1-MAY-2020)

Sample: Use the *Sample solution* prepared for the Assay.

Acceptance criteria: Meets the requirements

- **B.**

Sample solution: Nominally 20 mg/mL of floxuridine in water

Analysis: Add a few drops of bromine TS to 10 mL of the *Sample solution*.

Acceptance criteria: The bromine color is discharged.

ASSAY

- **PROCEDURE**

Diluent: Potassium hydroxide solution (1 in 180)

Standard solution: 20 µg/mL of [USP Floxuridine RS](#) in *Diluent*

Sample stock solution: Nominally 0.4 mg/mL of Floxuridine for Injection in *Diluent*

Sample solution: 20 µg/mL from the *Sample stock solution* in *Diluent*

Blank: *Diluent*

Instrumental conditions

Mode: UV

Analytical wavelength: 268 nm

Cell: 1 cm

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of floxuridine ($C_9H_{11}FN_2O_5$) in the portion of Floxuridine for Injection taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Floxuridine RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of floxuridine in the *Sample solution* (µg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

SPECIFIC TESTS

- [pH \(791\)](#)

Sample solution: 1 in 50

Acceptance criteria: 4.0–5.5

- **CONSTITUTED SOLUTION:** Meets the requirements in [Injections and Implanted Drug Products \(1\), Specific Tests, Completeness and clarity of solutions](#)

• **PYROGEN:** Meets the requirements of [Pyrogen Test \(151\)](#), the test dose being 0.50 mL/kg of a solution prepared by diluting Floxuridine for Injection with Sodium Chloride Injection to a concentration of 100 mg/mL

- **OTHER REQUIREMENTS:** Meets the requirements in [Injections and Implanted Drug Products \(1\)](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging](#), and protect from light. Store containers of constituted Floxuridine for Injection under refrigeration for NMT 2 weeks.
- **USP REFERENCE STANDARDS (11).**
[USP Floxuridine RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FLOXURIDINE FOR INJECTION	Documentary Standards Support	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-37D06194-CD47-41B2-806F-04B676123CC0_2_en-US

DOI: https://doi.org/10.31003/USPNF_M33210_02_01

DOI ref: [2yql7](#)

OFFICIAL